Leishmaniasis is a tropical disease caused by the intracellular obligate protozoan from the genre Leishmania. Its cycle of transmission is mediated by the bite of the phlebotomus insect. The infective forms of the parasite are the metacyclic promastigote and amastigotes. Depending on the Leishmania species and the immunological state of the host, there could be established different manifestations of the disease. The parasite virulence has been associated to its capacity of survival inside the activated macrophage. Furthermore, in the internal atmosphere of the cell are present different immunomodulation mechanisms that control the activation of the cell immune response. The CD200 protein is a glycoprotein with the capacity to regulate the activation of macrophages by binding to the CD200R receptor and generating an inhibition pathway leading to its inactivation. It has been demonstrated that the induced expression of CD200 protein in the infective process of L. amazonensis reduces the cellular response of the macrophage enhancing the parasite intracellular survival. That's why it is important not only to study the differential expression of CD200 in different Leishmania species which present a similar pathology, but to also determine if the expression of CD200 will vary significantly depending on the disease developed. To answer this question, there will be executed different in vitro and in vivo infections in phagocytic cells and mice with different isolates of L. amazonensis associated to patients with localized cutaneous leishmaniasis (LCL) and difused cutaneous leishmaniasis (DCL). There will be done tests to quantify the expression of CD200 in the infective process.
News published in Agência FAPESP Newsletter about the scholarship: